Physician profile
Michael Levangie
NPI 1891707816
$5,465.49
in general payments reported to CMS, 2019-2025
37 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $922 · 2021: $1,303 · 2022: $673 · 2023: $702 · 2024: $256 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $714.98 | 2019-2025 | |
| Abbott Laboratories | $630.39 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amarin Pharma, INC. | $517.30 | 2019-2021 | |
| Amgen INC. | $481.99 | 2019-2023 | Repatha |
| Esperion Therapeutics, INC. | $341.38 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $258.17 | 2019-2023 | |
| Boston Scientific Corporation | $243.82 | 2020-2024 | Watchman, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $235.39 | 2019-2022 | |
| Medtronic, INC. | $222.81 | 2021-2023 | Corevalve Evolut R |
| Atricure, INC. | $203.36 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $176.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $175.97 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.91 | 2019-2023 | Jardiance |
| Pfizer INC. | $136.21 | 2019-2025 | |
| Medtronic Vascular, INC. | $116.69 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $105.43 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $91.62 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $75.92 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.78 | 2021-2025 | |
| Lundbeck LLC | $51.80 | 2019-2020 | |
| Edwards Lifesciences Corporation | $49.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $48.49 | 2019 | |
| Arbor Pharmaceuticals, INC. | $47.67 | 2020-2021 | |
| Daiichi Sankyo INC. | $45.46 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $34.17 | 2021 | |
| Novo Nordisk INC | $33.66 | 2019-2023 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $30.42 | 2019 | |
| Genzyme Corporation | $23.82 | 2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $23.32 | 2022 | |
| Kestra Medical Technology Services, INC. | $19.49 | 2023 | Assure Wcd |
| Vifor Pharma, INC. | $18.40 | 2021 | |
| Bardy Diagnostics, INC. | $18.20 | 2021 | |
| Astellas Pharma US INC | $17.73 | 2019 | |
| Irhythm Technologies, INC. | $16.51 | 2019 | |
| Amryt Pharma Holdings Ltd | $16.18 | 2021 | |
| Ge Healthcare | $15.37 | 2019 | |
| G Medical Diagnostic Services, INC. | $11.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levangie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.